The first biologic that was developed and demonstrated efficacy in severe asthma is omalizumab (1–4), which is a humanized anti-IgE mAb that binds the C3 region of the IgE-Fc fragment and captures circulating IgE, preventing interaction with the FcεRI and thus interrupting the allergic cascade (70). The gene discussed is IGHE; the disease is asthma.